ДОМЕНИЧИ Лучано (HU),ДЖОВАННИНИ Лука (HU),САНСО Марко (HU)
申请号：
RU2012120096/15
公开号：
RU2012120096A
申请日:
2010.11.12
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. An ophthalmic preparation in the form of eye drops containing a neurotrophic factor of the brain (BDNF) at a concentration of at least 15 μg / μl. 2. The ophthalmic preparation according to claim 1, in which the concentration of BDNF is from 15 to 200 μg / μl. Ophthalmic preparation according to claim 1 or 2, additionally containing physiological saline as a pharmaceutically acceptable carrier. The ophthalmic preparation according to claim 1, wherein the physiological saline solution contains 0.9% sodium chloride. The ophthalmic preparation according to claim 1, further comprising a solution with a high viscosity as an additional pharmaceutically acceptable carrier. The ophthalmic preparation according to claim 1, in which the solution with increased viscosity is a solution containing a polysaccharide extracted from the seeds of Indian date (TSP). The ophthalmic preparation according to claim 1, wherein the TSP concentration is from 0.05 to 2% w / v. The ophthalmic preparation according to claim 1, further comprising hyaluronic acid. The ophthalmic preparation according to claim 1, wherein the high viscosity solution contains TSP and hyaluronic acid. An ophthalmic preparation in the form of eye drops containing BDNF, intended to prevent and / or treat neurodegenerative diseases of the retina, optic nerve and lateral cranked body. 11. The ophthalmic preparation of claim 10, intended to prevent and / or treat retinal pigment dystrophy. The ophthalmic preparation of claim 10, designed to prevent and / or treat chronic simple glaucoma.1. Офтальмологический препарат в форме глазных капель, содержащий нейротрофический фактор головного мозга (BDNF) в концентрации, по меньшей мере, 15 мкг/мкл.2. Офтальмологический препарат по п.1, в котором концентрация BDNF составляет от 15 до 200 мкг/мкл.3. Офтальмологический препарат по п.1 или 2, дополнительно содержащий физиологический раствор в качестве фармацевтически приемлемого носителя.4. Офтальмологический препарат по п.1, в к
